INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated March 30, 2023, reports on INVO Bioscience, Inc. (trading symbol: INVO), a Nevada corporation. The filing announces preliminary financial results for the fourth quarter and the full year ended December 31, 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
No specific material changes versus prior periods are detailed in the text of this 8-K. The document serves as a notification that preliminary results have been issued.
Guidance, Outlook, and Risks
The filing includes a standard Regulation FD disclosure and notes that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Pricing Press Release) for actual Q4 and full-year 2022 financial figures.
- Verify the company's current cash position and runway based on the preliminary results.
- Confirm any updates to the company's product pipeline or regulatory status mentioned in the press release.
- Check for any forward-looking statements or guidance provided in the referenced press release.